logo-loader
viewMediWound Ltd

MediWound stock climbs after 4Q revenue swells past Street estimates

The Israel-based biopharma plans to file a biologics license application for NexoBrid, which removes dead tissue from severe burns in the second half of 2019

A burn patient receiving treatment
The biopharma's flagship drug NexoBrid removes dead tissue resulting from a severe burn

MediWound Ltd (NASDAQ:MDWD) rose Monday after the biopharma focusing on severe burn and wound management posted a narrower fourth-quarter loss on strong revenue.

For the quarter ended December 2019, the Yavne, Israel-based company posted a loss of $0.06 per share on revenue of $1 million. The consensus estimate was a loss of $0.15 per share on revenue of $0.8 million. Revenue grew 87.2% on a year-over-year basis.

Shares in MediaWound climbed 7.5% to $5.58 before the opening bell.

READ: MediWound climbs after reporting positive results from Phase 3 burn treatment clinical study

In January, the company announced positive top-line results from the Phase 3 DETECT study in NexoBrid which removes dead tissue resulting from a severe burn.

MediWound plans to file a biologics license application for NexoBrid in the second half of 2019. A biologics license application is a request to distribute a biologic across states.

“We plan to file the biologics license application in the second half of 2019, subject to Food and Drug Administration concurrence in a meeting planned for the second quarter,” MediWound CEO Gal Cohen said in a statement.

Cohen announced earlier in March that he will step down as CEO by the end of May and that Sharon Malka, the company’s chief operating officer and CFO will assume the role of CEO at that time.

The niche company specializes in developing therapeutics to treat conditions related to severe burns and chronic or slow-to-heal wounds.

Contact Uttara Choudhury at [email protected]

Follow her on Twitter@UttaraProactive 

 

Quick facts: MediWound Ltd

Price: 3 USD

NASDAQ:MDWD
Market: NASDAQ
Market Cap: $81.54 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Tocvan preparing for a busy 2020 on a project in Mexico with...

Tocvan (CSE: TOC) Director Brodie Sutherland joined Steve Darling in the Vancouver studio of Proactive to discuss the company’s Mexican asset. Sutherland talked about the history of the project and the advantages they have because of the location.  Sutherland also told Proactive what...

11 hours, 8 minutes ago

2 min read